diflunisal


Also found in: Dictionary, Thesaurus, Wikipedia.

diflunisal

 [di-floo´nĭ-sal]
a salicylic acid derivative that, like aspirin, has analgesic and antiinflammatory properties, although no antipyretic effects, but has fewer side effects than aspirin, does not affect bleeding time or function, and has a long half-life that permits twice daily dosage. It is used in the treatment of rheumatic and nonrheumatic inflammatory disorders, gout and calcium pyrophosphate deposition disease, dysmenorrhea, and vascular headaches.

diflunisal

/di·flu·ni·sal/ (di-floo´nĭ-sal) a nonsteroidal antiinflammatory drug that lacks antipyretic activity; used in the treatment of rheumatic and nonrheumatic inflammatory disorders, gout and calcium pyrophosphate deposition disease, dysmenorrhea, and vascular headaches.

diflunisal

(dī-flo͞o′nĭ-săl′, -sôl′)
n.
A nonsteroidal anti-inflammatory drug that is a derivative of salicylic acid and is used to treat inflammation and mild to moderate pain.

diflunisal

[dīflo̅o̅′nisal]
a nonsteroidal antiinflammatory drug.
indications It is prescribed for the treatment of mild to moderate pain and inflammation in osteoarthritis and other musculoskeletal disorders.
contraindications Hypersensitivity to aspirin and other nonsteroidal antiinflammatory drugs or known sensitivity to this drug prohibits its use.
adverse effects The most serious adverse reactions are GI pain, diarrhea, peptic ulcer, anorexia, anaphylactoid reactions with bronchospasm, and edema.

diflunisal

A non-steroidal pain-killing and anti-inflammatory drug (NSAID). It is a derivative of SALICYLIC ACID and is used to control symptoms in OSTEOARTHRITIS and other painful conditions. A brand name is Dolobid.

diflunisal

(dīfloo´nəsal´),
n brand name: Dolobid;
drug class: salicylate derivative, nonsteroidal antiinflammatory;
action: inhibits prostaglandin synthesis;
uses: mild to moderate pain, symptoms of rheumatoid arthritis and osteoarthritis.

diflunisal

a salicylic acid derivative that, like aspirin, has analgesic and anti-inflammatory properties.
References in periodicals archive ?
CRx-401: an interim analysis on the first 50 subjects enrolled in the CRx-401 phase 2 clinical study in Type 2 diabetes indicates that the trial is unlikely to detect a treatment advantage of the CRx-401 combination of bezafibrate and diflunisal over bezafibrate alone.
One study that directly compared diflunisal with naproxen for lateral epicondylitis found no difference between the therapies in patients' subjective perception of pain on a 5-point scale (RR=0.
The plates were washed six times with the wash buffer, and then 100 [micro]L of diflunisal phosphate solution [0.
Our decision to market a generic version of diflunisal was based on the goals of generating revenues to support our research and development program and to satisfy the preference of some customers for generic products," says a company spokeswoman.
CRx-401 is a synergistic combination drug candidate containing sustained-release bezafibrate, an anti-cholesterol agent approved outside the United States, and a low dose of diflunisal, a widely available analgesic.
Nonsteroidal anti-inflammatory agents include the traditional nonselective NSAIDs (ibuprofen, indomethacin, diclofenac, diflunisal, naproxen, etc), the cyclooxygenase-2 (COX-2) selective inhibitors (celecoxib, rofecoxib, valdecoxib), aspirin, and the nonacetylated salicylates (choline salicylate or magnesium salicylate).
We measured the alkaline phosphatase activity by adding the substrate diflunisal phosphate, incubating for 10 min, and then adding a [Tb.
Based on this encouraging preclinical data, CRx-401, a novel synergistic combination containing the cholesterol agent bezafibrate and a low dose of the analgesic diflunisal, has been selected as a clinical product candidate with a phase 2a clinical trial in type 2 diabetes expected to begin mid-2007.
She was given a prescription for diflunisal, 500 mg twice a day, and was asked to follow up in 2 weeks.
CRx-401 contains the cholesterol agent bezafibrate and a low dose of the analgesic diflunisal, neither of which is indicated for the treatment of diabetes on its own, but which have been shown in preclinical studies to act synergistically to increase insulin sensitivity and lower plasma glucose without causing weight gain.